Please assess the completion status of the following clinical trial:

Trial Title: 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 42 to 70 days at enrollment.~* Determined by medical history, physical examination, and clinical judgment to be eligible for the study~* Weight of 3.5 kg or greater at the time of enrollment~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal vaccine.~* A previous anaphylactic reaction to any vaccine or vaccine-related component.~* Contraindication to vaccination with pneumococcal conjugate vaccine.~* Receipt of blood products or gamma-globulin since birth

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 70 Days
- Healthy Volunteers: t

Study Arms:
- Multidose Vial Group (Type: EXPERIMENTAL): Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
- Single-Dose Syringe Group (Type: ACTIVE_COMPARATOR): Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).